HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi May Split Up Beauty Brands To Help Saleability Of Business

This article was originally published in The Rose Sheet

Executive Summary

Sanofi will divest its beauty business by the end of 1999 and may divide up the sale offering to separate its prestige brands, which include Yves Saint Laurent and Oscar de la Renta, from Yves Rocher, which is sold via mailorder in the U.S. The Dec. 2 announcement of the Sanofi beauty business sell-off occurred simultaneously with the Paris-based pharmaceutical firm's proposed merger with the French pharmaceutical company Synthelabo, which is owned in part by L'Oreal.

You may also be interested in...



Gucci Acquires $583.4 Mil. Sanofi Beauty Business From Artemis

Gucci is purchasing Sanofi Beaute from Artemis for $1 bil., giving the fashion house Yves Saint Laurent fragrances and cosmetics, Roger & Gallet, and fragrance licenses for Van Cleef & Arpels, Oscar de la Renta, Fendi and Krizia. Sanofi beauty sales total $583.4 mil.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel